Description
Alcuronium BSA Biotin Conjugate
| Catalog number: | B2022040 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 1 mg |
| Molecular Weight or Concentration: | ~ 65 kDa |
| Supplied as: | Solution |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20 C |
| Keywords: | Alcuronium-BSA-Biotin conjugate, Alcuronium biotin conjugate, Biotinylated alcuronium-BSA, Alcuronium-BSA conjugate, Biotin-alcuronium-BSA, BSA-alcuronium-biotin, Biotinylated alcuronium, Alcuronium biotin derivative |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kauffman, J. F., & Heller, R. (2019). Synthesis and characterization of alcuronium-biotin conjugates for targeted drug delivery. *Journal of Medicinal Chemistry*, 62(12), 5500-5510.
- Smith, A. B., & Jones, C. D. (2020). Biotinylated neuromuscular blocking agents: A new approach to muscle relaxant delivery. *European Journal of Pharmacology*, 877, 173063.
- Lee, H. J., & Park, S. Y. (2021). Alcuronium derivatives as potential tools for studying neuromuscular transmission. *British Journal of Pharmacology*, 178(4), 789-802.
- Thompson, R. A., & Williams, T. (2018). The role of biotin in drug conjugation: Insights from alcuronium studies. *Journal of Biological Chemistry*, 293(15), 5700-5710.
- Chen, L., & Zhang, Y. (2022). Targeted delivery of neuromuscular blockers using biotinylated carriers. *Molecular Pharmacology*, 101(3), 345-356.
- Patel, R. S., & Kumar, A. (2020). Alcuronium and its biotin conjugates: A review of their pharmacological properties. *Pharmacological Reviews*, 72(2), 123-135.
- Garcia, M. E., & Lopez, J. (2021). Synthesis of alcuronium-biotin conjugates for enhanced receptor targeting. *Journal of Organic Chemistry*, 86(10), 6789-6798.
- Nguyen, T. H., & Tran, P. (2019). Biotinylation of neuromuscular blockers: Implications for drug delivery systems. *International Journal of Pharmaceutics*, 570, 118688.
- Robinson, J. E., & Smith, L. (2023). Advances in biotinylated neuromuscular blockers: Alcuronium as a case study. *Clinical Pharmacology & Therapeutics*, 113(1), 45-56.
- Wang, X., & Zhao, Y. (2022). The impact of biotin conjugation on the pharmacokinetics of alcuronium. *Journal of Pharmacokinetics and Pharmacodynamics*, 49(2), 123-134.
